The monarchE study was a multicenter cooperative non-blind randomized Phase III trial in patients with HR-positive HER2-negative breast cancer with a high risk of recurrence that examined addition of 2-year concurrent administration of abemaciclib to standard adjuvant ET after standard treatments such as surgery, neoadjuvant/adjuvant chemotherapy, and radiotherapy [6]. This evidence concerns the gene ERBB2 and breast cancer.